表紙
市場調查報告書

勃起功能障礙(ED)治療藥的全球市場:2019年∼2023年

Global Erectile Dysfunction (ED) Drugs Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 312457
出版日期 內容資訊 英文 121 Pages
訂單完成後即時交付
價格
勃起功能障礙(ED)治療藥的全球市場:2019年∼2023年 Global Erectile Dysfunction (ED) Drugs Market 2019-2023
出版日期: 2019年03月27日內容資訊: 英文 121 Pages
簡介

ED症狀的高盛行率,預計是在未來幾年內引發市場成長的關鍵因素之一。各種健康狀況包括糖尿病,高血壓,肥胖,抑鬱,壓力和過量飲酒導致老年人和年輕人的ED發病率上升。由於這些條件直接改變了激素,酶和其他因素的正常生理水平,近年來包括陰莖勃起在內的問題急劇增加。這些問題將進一步導致勃起功能障礙藥物市場在未來幾年出現顯著成長。Technavio的分析師預測,到2023年,勃起功能障礙(ED)藥物市場的年複合成長率將超過4%。

本報告提供全球勃起功能障礙(ED)治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 報告的範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 開發平台分析

第5章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第6章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第7章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 口服藥
  • 外用藥
  • 其他
  • 市場機會:各產品

第8章 客戶形勢

第9章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第10章 決策架構

第11章 成長要素與課題

  • 市場成長要素
  • 市場課題

第12章 市場趨勢

第13章 業者情勢

  • 概要
  • 創造性破壞狀況

第14章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Bayer AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS Inc.

第15章 附錄

  • 調查方法
  • 簡稱的清單

第16章 關於TECHNAVIO

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR31071

About this market

The high prevalence of conditions resulting in ED is one of the key factors expected to trigger the market's growth in the forthcoming years. Various health conditions including diabetes, hypertension, obesity, depression, stress, and excessive alcohol consumption are resulting in the rising incidences of ED among elderly as well as young people. As these conditions directly alter the normal physiological levels of hormones, enzymes, and other factors, problems including penile erection have surged considerably in the recent years. These issues will further lead the erectile dysfunction drugs market to register a significant growth in the forthcoming years. Technavio's analysts have predicted that the erectile dysfunction (ED) drugs market will register a CAGR of over 4% by 2023.

Market Overview

Rising demand for ED drugs

One of the growth drivers of the global erectile dysfunction (ED) drugs market is the rising demand for ED drugs. The rising cyberpornography and the increasing number of advertisements for the treatment of ED are expected to propel the growth of the global erectile dysfunction (ED) drugs market during the forecast period.

Side effects of available drugs

One of the challenges in the growth of the global erectile dysfunction (ED) drugs market is the side effects of available drugs. The alterations in the blood flow, which are caused by ED drugs, result in side-effects such as headache, vision changes, and dizziness, which will hinder the growth of the market.

For the detailed list of factors that will drive and challenge the growth of the erectile dysfunction (ED) drugs market during 019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated with the presence of a few market players. Many vendors in the market are focusing on expanding research for the development of novel therapies such as stem cells for the treatment of ED. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Oral drugs - Market size and forecast 2018-2023
  • Topical drugs - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS Inc.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline molecules for ED
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Oral drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Oral drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Sales of VIAGRA and CIALIS 2016-2018
  • Exhibit 23: Topical drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Topical drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Market opportunity by product
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Impact of drivers and challenges
  • Exhibit 42: Vendor landscape
  • Exhibit 43: Landscape disruption
  • Exhibit 44: Vendors covered
  • Exhibit 45: Vendor classification
  • Exhibit 46: Market positioning of vendors
  • Exhibit 47: Bayer AG - Vendor overview
  • Exhibit 48: Bayer AG - Business segments
  • Exhibit 49: Bayer AG - Organizational developments
  • Exhibit 50: Bayer AG - Geographic focus
  • Exhibit 51: Bayer AG - Segment focus
  • Exhibit 52: Bayer AG - Key offerings
  • Exhibit 53: Eli Lilly and Company - Vendor overview
  • Exhibit 54: Eli Lilly and Company - Business segments
  • Exhibit 55: Eli Lilly and Company - Organizational developments
  • Exhibit 56: Eli Lilly and Company - Geographic focus
  • Exhibit 57: Eli Lilly and Company - Segment focus
  • Exhibit 58: Eli Lilly and Company - Key offerings
  • Exhibit 59: Pfizer Inc. - Vendor overview
  • Exhibit 60: Pfizer Inc. - Business segments
  • Exhibit 61: Pfizer Inc. - Organizational developments
  • Exhibit 62: Pfizer Inc. - Geographic focus
  • Exhibit 63: Pfizer Inc. - Segment focus
  • Exhibit 64: Pfizer Inc. - Key offerings
  • Exhibit 65: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 66: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 67: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 68: Teva Pharmaceutical Industries Ltd. - Geographic focus
  • Exhibit 69: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 70: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 71: VIVUS Inc. - Vendor overview
  • Exhibit 72: VIVUS Inc. - Business segments
  • Exhibit 73: VIVUS Inc. - Organizational developments
  • Exhibit 74: VIVUS Inc. - Geographic focus
  • Exhibit 75: VIVUS Inc. - Key offerings
  • Exhibit 76: Validation techniques employed for market sizing